Soaring Demand Set to Propel Chromatin immunoprecipitation (ChIP) Sequencing Market to $25.37 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Chromatin immunoprecipitation (ChIP) Sequencing Market Through 2025?
In recent times, the market size for chromatin immunoprecipitation (ChIP) sequencing has experienced substantial growth. The market size is projected to increase from $13.89 billion in 2024 to $15.6 billion in 2025, at a compound annual growth rate (CAGR) of 12.3%. Factors contributing to this growth during the historic period include an improved understanding of gene regulation, an increase in epigenetics studies, advancement in data analysis and bioinformatics tools, and reductions in cost coupled with scalability.

What's the Projected Size of the Global Chromatin immunoprecipitation (ChIP) Sequencing Market by 2029?
Predictions indicate a swift expansion for the chromatin immunoprecipitation (ChIP) sequencing market in the upcoming years, reaching a valuation of $25.37 billion in 2029. This growth, which represents a compound annual growth rate (CAGR) of 12.9%, is forecasted due to factors such as industry investment and rivalry, clinical uptake and diagnostic uses, an increasing need for biomarker discovery, and the fast-paced evolution of bioinformatics tools. Additionally, the widening applications in drug discovery contribute to the growth. The upcoming major trends for the market throughout the forecast period comprise clinical translation and diagnostic applications, an emphasis on histone modifications, and expanding applications in novel research fields. Advancements in the preparation of samples and the integration of multi-omics are also anticipated.

View the full report here:
https://www.thebusinessresearchcompany.com/report/chromatin-immunoprecipitation-chip-sequencing-global-market-report

Top Growth Drivers in the Chromatin immunoprecipitation (ChIP) Sequencing Industry: What's Accelerating the Market?
The rise in prostate cancer occurrences is projected to fuel the expansion of the chromatin immunoprecipitation (ChIP) sequencing market. Prostate cancer, which forms in the prostate gland - a gland in men that aids in the production of semen - is a disease where ChIP-seq offers invaluable insights into the molecular events steering the disease. These findings can offer a deeper knowledge of the disease's biology and assist in the formation of more refined and effective treatment strategies. For instance, the American Cancer Society, a U.S.-based cancer-fighting organization, stated in January 2023 that an estimated 288,300 new prostate cancer cases were recorded, with 34,700 fatalities from the disease in the US alone in 2023. Therefore, the rising incidence of prostate cancer is the primary factor behind the growth of the chromatin immunoprecipitation (ChIP) sequencing market. The chromatin immunoprecipitation (ChIP) Sequencing market is also being driven by the rising need for personalized medicine, anticipated to push the market expansion forward. Personalized medicine is a novel method in healthcare where specific treatments are tailored according to each patient's unique characteristics. It often relies on the identification of specific genetic or epigenetic markers tied to different diseases. Here, ChIP sequencing emerges as a robust instrument for tracking epigenetic alterations like DNA methylation and histone modifications, enabling a comprehensive understanding of the genetic groundwork of diseases. As an example, in 2022, the Personalized Medicine Coalition, a U.S.-based professional membership organization, reported that the FDA's Center for Drug Evaluation and Research approved 37 new molecular entities (NMEs). Out of the 35 therapeutic NMEs, the Personalized Medicine Coalition designated 12, or around 34%, as custom-made medications. Hence, the rising acceptance of personalized medicine is propelling the growth of the chromatin immunoprecipitation (ChIP) sequencing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13265&type=smp

What Trends Will Shape the Chromatin immunoprecipitation (ChIP) Sequencing Market Through 2029 and Beyond?
Top businesses in the chromatin immunoprecipitation (ChIP) sequencing market are concentrating on innovative technologies, like hmqChIP-seq (high-throughput multiplex quantitative Chromatin Immunoprecipitation sequencing), to improve the effectiveness and precision of epigenomic studies, thereby fuelling progress in drug discovery and individualized medicine. hmqChIP-seq is a revolutionary technology designed to advance the investigation of epigenetic alterations across the genome. For example, in June 2024, Epigenica, a company specializing in life sciences technology based in Sweden, introduced its EpiFinder Platform, which incorporates patented hmqChIP-seq technology, thereby allowing for efficient, multiplex quantitative analysis in epigenomic research. This groundbreaking platform empowers researchers to produce 192 genome-wide profiles simultaneously from a maximum of 24 samples, making large-scale experiments more streamlined, faster, and cost-effective.

What Are the Main Segments in the Chromatin immunoprecipitation (ChIP) Sequencing Market?
The chromatin immunoprecipitation (ChIP) sequencing market covered in this report is segmented -

1) By Type: DNase-Sequencing, FAIRE-Sequencing
2) By Technology: Targeted Sequencing And Re-Sequencing, Whole Genome Sequencing And Whole Exome Sequencing
3) By Workflow: Pre-Sequencing, Sequencing, Data Analysis
4) By Application: Consumables And Reagents, Service, Other Applications
5) By End-User: Academic Research Institutes, Clinical Research Institutes, Hospitals And Clinics, Pharmaceuticals And Biotechnology Companies, Other End Users

Subsegments:
1) By DNase-Sequencing: DNase I Hypersensitivity Mapping, DNase-Seq For Open Chromatin Regions
2) By FAIRE-Sequencing: Formaldehyde-Assisted Isolation Of Regulatory Elements (FAIRE), FAIRE-Seq For Active Regulatory Regions

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13265&type=smp

Which Top Companies are Driving Growth in the Chromatin immunoprecipitation (ChIP) Sequencing Market?
Major companies operating in the chromatin immunoprecipitation (chip) sequencing market report are F. Hoffmann La Roche Ltd., Merck KGaA, Thermo Fisher Scientific Inc., Becton Dickinson and Co., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Bio-Techne Corp., BGI Genomics Co. Ltd., Promega Corporation, GenScript Biotech Corporation, Abcam PLC, BioLegend Inc., Hamilton Co., Takara Bio Inc., Novogene Co. Ltd., Oxford Nanopore Technologies PLC, Porvair Sciences Ltd., Creative Biolabs Inc., Cell Signaling Technology Inc., GENEWIZ Inc., Zymo Research Corporation, CD Genomics, Active Motif Inc., Psomagen Inc., EpiCypher Inc.

Which Regions Will Dominate the Chromatin immunoprecipitation (ChIP) Sequencing Market Through 2029?
North America was the largest region in the chromatin immunoprecipitation (ChIP) sequencing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chromatin immunoprecipitation (chip) sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13265

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.